A Comparison of the Risk of QT Prolongation Among SSRIs

Annals of Pharmacotherapy

Volumn 47, Issue 10, 2013, Pages 1330-1341

  Funk, Kylee A ^a,b   Bostwick, Jolene R ^a,b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

QTc prolongation; SSRI; torsades de pointes

Indexed keywords

CITALOPRAM; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ACUTE CORONARY SYNDROME; ARTICLE; COMPARATIVE STUDY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HEART ARRHYTHMIA; HUMAN; MONOTHERAPY; PRIORITY JOURNAL; QT PROLONGATION; RISK ASSESSMENT; RISK FACTOR; TORSADE DES POINTES;

QTC PROLONGATION; SSRI; TORSADES DE POINTES;

ANTIDEPRESSIVE AGENTS; HUMANS; LONG QT SYNDROME; RISK; SEROTONIN UPTAKE INHIBITORS;

EID: 84888053567     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028013501994     Document Type: Article

References (62)

1. Leonard CE,Bilker WB,Newcomb C,Kimmel SE,Hennessy S.Antidepressants and the risk of sudden cardiac death and ventricular arrhythmia.Pharmacoepidemiol Drug Saf. 2011;20:903-913.
2. Weeke P,Jensen A,Folke Fet al.Antidepressant use and risk of out-of-hospital cardiac arrest: a nationwide case-time-control study.Nature. 2012;92:72-79.
3. Martinez C,Assimes TL,Mines D,Dell'aniello S,Suissa S.Use of venlafaxine compared with other antidepressants and the risk of sudden cardiac death or near death: a nested case-control study.BMJ. 2010;340:c249.
4. Glassman AH,Bigger JT.Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.Am J Psychiatry. 2001;158:1774-1782.
5. US Department of Health and Human Services. Guidance for industry: E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm129357.pdf. Accessed March 23, 2013.
6. US Food and Drug Administration. FDA drug safety communication: abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm. Accessed November 18, 2012.
7. Medicines and Healthcare Products Regulatory Agency. Citalopram and escitalopram: QT interval prolongation: new maximum daily dose restrictions (including in elderly patients), contraindications and warnings. http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON137769. Accessed March 23, 2013.
8. US Food and Drug Administration. Drug development and drug interactions: table of substrates, inhibitors, and inducers. http://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm. Accessed May 12, 2013.
9. Vieweg WV,Hasnain M,Howland RHet al.Citalopram, QTc interval prolongation, and torsade de pointes: how should we apply the recent FDA ruling?.Am J Med. 2012;125:859-868.
10. Howland RH.A critical evaluation of the cardiac toxicity of citalopram: part 1.J Psychosoc Nurs Ment Health Serv. 2011;49:13-16.
11. Lexapro (escitalopram) [product information]. St Louis, MO: Forest Pharmaceuticals, Inc; 2012
12. Castro VM,Clements CC,Murphy SNet al.QT interval and antidepressant use: a cross sectional study of electronic health records.BMJ. 2013;346:f288.
13. Hanash JA,Hansen BH,Hansen JF,Nielsen OW,Rasmussen A,Birket-Smith M.Cardiovascular safety of 1-year escitalopram therapy in clinically nondepressed patients with acute coronary syndrome.J Cardiovasc Pharmacol. 2012;60:397-405.
14. Tseng PT,Lee Y,Lin YE,Lin PY.Low-dose escitalopram for 2 days associated with corrected QT interval prolongation in a middle-aged woman: a case report and literature review.Gen Hosp Psychiatry. 2012;34:210.e13-210.e15.
15. Arizona CERT. QT drug lists by risk groups. http://www.azcert.org/medical-pros/drug-lists/drug-lists.cfm. Accessed March 23, 2013.
16. Strik JJMH,Honig A,Lousberg Ret al.Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: findings from a doubleblind, placebo-controlled trial.Psychosom Med. 2000;62:783-789.
17. Upward JW,Edwards JG,Goldie A,Waller DG.Comparative effects of fluoxetine and amitriptyline on cardiac function.Br J Clin Pharmacol. 1988;26:399-402.
18. Baker B,Dorian P,Sandor Pet al.Electrocardiographic effects of fluoxetine and doxepin in patients with major depressive disorder.J Clin Psychopharmacol. 1997;17:15-21.
19. Roose SP,Glassman AH,Attia E,Woodring S,Giardina EG,Bigger JT.Cardiovascular effects of fluoxetine patients with heart disease.Am J Psychiatry. 1998;155:660-665.
20. Zhao Q,Wojcik MA,Parier JL,Pesco-Koplowitz L.Influence of coadministration of fluoxetine on cisapride pharmacokinetics and QTc intervals in healthy volunteers.Pharmacotherapy. 2001;21:149-157.
21. Henry ME,Schmidt ME,Hennen Jet al.A comparison of brain and serum pharmacokinetics of R-fluoxetine and racemic fluoxetine: a 19-F MRS study.Neuropsychopharmacology. 2005;30:1576-1583.
22. Prozac (fluoxetine) [product information]. Indianapolis, IN: Eli Lilly and Company, Jan 2013.
23. Michalets EL,Smith LK,Van Tassel ED.Torsade de pointes resulting from the addition of droperidol to an existing cytochrome P450 drug interaction.Ann Pharmacother. 1998;32:761-765.
24. Nykamp DL,Blackmon CL,Schmidt PE,Roberson AG.QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine.Ann Pharmacother. 2005;39:543-546.
25. Deamer RL,Wilson DR,Clark DS,Prichard JG.Torsades de pointes associated with high dose levomethadyl acetate (ORLAAM).J Addict Dis. 2001;20:7-14.
26. Dubnov G,Fogelman R,Merlob P.Prolonged QT interval in an infant of a fluoxetine treated mother.Arch Dis Child. 2005;90:972-973.
27. Varriale P.Fluoxetine (prozac) as a cause of QT prolongation.Arch Intern Med. 2001;161:612.
28. Wilting I,Smals OM,Holwerda NJ,Meyboom RH,de Bruin ML,Egberts TC.QTc prolongation and torsades de pointes in an elderly woman taking fluoxetine.Am J Psychiatry. 2006;163:325.
29. Okayasu H,Ozeki Y,Fujii Ket al.Pharmacotherapeutic determinants for QTc interval prolongation in Japanese patients with mood disorder.Pharmacopsychiatry. 2012;45:279-283.
30. Sadanaga T,Sadanaga F,Yao H,Fujishima M.Abnormal QT prolongation and psychotropic drug therapy in psychiatric patients: significance of bradycardia-dependent QT prolongation.J Electrocardiol. 2004;37:267-273.
31. Hochberg HM,Kanter D,Houser VP.Electrocardiographic findings during extended clinical trials of fluvoxamine in depression: one years experience.Pharmacopsychiatry. 1995;28:253-256.
32. Rodriguez de la Torre B,Dreher J,Malevany Jet al.Serum levels and cardiovascular effects of tricyclicantidepressants and selective serotonin reuptake inhibitors in depressed patients.Ther Drug Monit. 2001;23:435-440.
33. Laird LK,Lydiard RB,Morton WAet al.Cardiovascular effects of imipramine, fluvoxamine, and placebo in depressed outpatients.J Clin Psychiatry. 1993;54:224-228.
34. Hewer W,Rost W,Gattez WF.Cardiovascular effects of fluvoxamine and maprotiline in depressed patients.Eur Arch Psychiatry Clin Neurosci. 1995;246:1-6.
35. Luvox (fluvoxamine) [product information]. Palo Alto, CA: Jazz Pharmaceuticals, Inc; 2012.
36. Brzozowska A,Werner B.Observation of QTc prolongation in an adolescent girl during fluvoxamine pharmacotherapy.J Child Adolesc Psychopharmacol. 2009;19:591-592.
37. Nelson JC,Lu Pritchett Y,Martynov O,Yu JY,Mallinckrodt CH,Detke MJ.The safety and tolerability of duloxetine compared with paroxetine and placebo: a pooled analysis of 4 clinical trials.Prim Care Companion J Clin Psychiatry. 2006;8:212-219.
38. Kuhs H,Rudolf GA.Cardiovascular effects of paroxetine.Psychopharmacology. 1990;102:379-382.
39. Edwards JG,Goldie A,Papayanni-Papasthatis S.Effect of paroxetine on the electrocardiogram.Psychopharmacology. 1989;97:96-98.
40. Yerangi VK,Pohl R,Jampala VC,Balon R,Ramesh C,Srinivasan K.Effects of nortriptyline and paroxetine on QT variability in patients with panic disorder.Depress Anxiety. 2000;11:126-130.
41. Martin DE,Zussman BD,Everitt DE,Benincosa LJ,Etheredge RC,Jorkasky DK.Paroxetine does not affect the cardiac safety and pharmacokinetics of terfenadine in healthy adult men.J Clin Psychopharmacol. 1997;17:451-459.
42. Potkin SG,Preskorn S,Hochfeld M,Meng X.A thorough QTc study of 3 doses of iloperidone including metabolic inhibition via CYP2D6 and/or CYP3A4 and a comparison to quetiapine and ziprasidone.J Clin Psychopharmacol. 2013;3:3-10.
43. Lim KS,Jang IJ,Kim BHet al.Changes in the QTc interval after administration of flecainide acetate, with and without coadministered paroxetine, in relation to cytochrome P450 2D6 genotype: data from an open-label, two-period, single-sequence crossover study in healthy Korean male subjects.Clin Ther. 2010;32:659-666.
44. Paxil (paroxetine) [product information]. Research Triangle Park, NC: GlaxoSmithKline; 2013.
45. Guy S,Silke B.The electrocardiogram as a tool for therapeutic monitoring: a critical analysis.J Clin Psychiatry. 1990;51:37-39.
46. Glassman AH,O'Connor CM,Califf RMet al.Sertraline treatment of major depression in patients with acute MI or unstable angina.JAMA. 2002;288:701-709.
47. Wilens TE,Biederman J,March JSet al.Absence of cardiovascular adverse effects of sertraline in children and adolescents.J Am Acad Child Adolesc Psychiatry. 1999;38:573-577.
48. Amin M,Lehmann H,Miriran J.A double-blind, placebo-controlled dose-finding study with sertraline.Psychopharmacol Bull. 1989;25:164-168.
49. Moeller O,Evers S,Deckert Jet al.The impact of ziprasidone in combination with sertraline on visually-evoked event-related potentials in depressed patients with psychotic features.Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:1440-1443.
50. Alderman J.Coadministration of sertraline with cisapride or pimozide: an open-label, nonrandomized examination of pharmacokinetics and corrected QT intervals in healthy adult volunteers.Clin Ther. 2005;27:1050-1063.
51. Hoehns JD,Fouts MM,Kelly MW,Tu KB.Sudden cardiac death with clozapine and sertraline combination.Ann Pharmacother. 2001;35:862-866.
52. Patane S,Marte F,Di Bella G.QT interval prolongation and torsade de pointes.Int J Cardiol. 2009;131:e51-e53.
53. Lynch DR,Washam JB,Newby LK.QT interval prolongation and torsades de pointes in a patient undergoing treatment with vorinostat: a case report and review of the literature.Cardiol J. 2012;19:434-438.
54. Zoloft (sertraline) [product information]. New York, NY: Pfizer; 2012.
55. Al-Khatib SM,LaPointe NM,Kramer JM,Califf RM.What clinicians should know about the QT interval.JAMA. 2003;289:2120-2127.
56. Rajamani S,Eckhardt LL,Valdivia CRet al.Drug-induced long QT syndrome: HERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine.Br J Pharmacol. 2006;149:481-489.
57. Isbister GK,Bowe SJ,Dawson A,Whyte IM.Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose.J Toxicol Clin Toxicol. 2004;42:277-285.
58. De Boer RA,van Dijk TH,Holman ND,van Melle JP.QT interval prolongation after sertraline overdose: a case report.BMC Emerg Med. 2005;5:5.
59. Poluzzi E,Raschi E,Moretti U,De Ponti F.Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS).Pharmacoepidemiol Drug Saf. 2009;18:512-518.
60. Zivin K,Pfeiffer PN,Bohnert ASBet al.Evaluation of the FDA warning against prescribing citalopram at doses exceeding 40 mg.Am J Psychiatry. 2013;170:642-650.
61. Teter CJ,Kando JC,Wells BGPharmacotherapy: A Pathophysiologic Approach. 8th ed.New York, NY: McGraw-Hill; 2011:chap 77.Talbert RLDiPiro JTMatzke GRPosey LMWells BGYee GC, ed. New York, NY: McGraw-Hill; 2011:77.
62. Practice guideline for the Treatment of Patients With Major Depressive Disorder. 3rd ed.Arlington, VA: American Psychiatric Publishing; 2010. doi:10.1176/appi.books.9780890423387.654001.Arlington, VA: American Psychiatric Publishing; 2010:.